Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T20:38:42.696Z.
Calculation as of: 2026-10-06T20:38:42.696Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$153.58M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$151.01M
EV/Sales Ratio
N/A
TTM Avg
975.23x
3Y Avg
975.23x
5Y Avg
975.23x
Market Cap
$149.36M
EV/Sales Ratio
N/A
TTM Avg
1521.81x
3Y Avg
1437.50x
5Y Avg
1437.50x
Market Cap
$148.73M
EV/Sales Ratio
77.54x
TTM Avg
3.64x
3Y Avg
6.48x
5Y Avg
6.15x
Market Cap
$148.64M
EV/Sales Ratio
4.22x
TTM Avg
6.09x
3Y Avg
3.52x
5Y Avg
3.55x
Market Cap
$148.27M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Veraxa Biotech Holding AG (VRXA) | $152.72M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | N/A | N/A | N/A |
| Neuronetics, Inc. (STIM)vs › | $153.79M | 1.43x | 1.39x | 1.55x | 1.31x |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | N/A | 975.23x | 975.23x | 975.23x |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | N/A | 1521.81x | 1437.50x | 1437.50x |
| Inogen, Inc. (INGN)vs › | $156.22M | 0.24x | 0.27x | 0.30x | 0.57x |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | 77.54x | 3.64x | 6.48x | 6.15x |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | 4.22x | 6.09x | 3.52x | 3.55x |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | N/A | 408.01x | 408.01x | 408.01x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
